Awry Dyken, controlier at Tamarikk Pharmsceutical fndustries, a public conpans ascurrently preparing the caleulation for busic and dituted earnings per share and the related diselosurefor Tarnarist's financial statenents. Pelow is selected financial infarmation for the fiscal year ended lure 30.2025. The following transactions have also occurred at Tamarisk. 1. Options were granted on July 1,2024, to purchase 220000 shares at $15 per share. Although na aptions were evercised during fiscal year 2025, the average price per corrmon share during facal year 2025 was $20 per share. 2. Each bond was issued at face value. The Bficonvertible bonds willconvert into econman stock at $0 shares per $1,000 bond The bonds are exercisable after 5 years and vere issued in fiscal year 2024. 3. The oreferred stock was issued in 2024 4. There are no peeferred dividends in arrears, towever, preferred cividends vere nat declared in fiscal year 2025. 5. The 1,000000 shares of cammon stock were outstanding for the entire 2005 fiscal year. 6. Net income for fical vear 2025 wan 51,500,000, and the averase incame tax rate is 20%